Target N V Biotech is > 10% Shareholder of Esperion Therapeutics, Inc.. Currently has a direct ownership of 4.48 Million shares of ESPR, which is worth approximately $10.2 Million. The most recent transaction as insider was on May 24, 2021, when has been sold 100,000 shares (Common Stock) at a price of $20.22 per share, resulting in proceeds of $2,022,000. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 4.48M
0% 3M change
0% 12M change
Total Value Held $10.2 Million

TARGET N V BIOTECH Transaction History

Date Transaction Value Shares Traded Shares Held Form
May 24 2021
BUY
Open market or private purchase
$2,022,000 $20.22 p/Share
100,000 Added 2.18%
4,477,964 Common Stock
May 19 2021
BUY
Open market or private purchase
$4,074,000 $20.37 p/Share
200,000 Added 4.37%
4,377,964 Common Stock
May 06 2021
BUY
Open market or private purchase
$1,645,600 $20.57 p/Share
80,000 Added 1.88%
4,177,964 Common Stock
May 05 2021
BUY
Open market or private purchase
$3,003,000 $20.02 p/Share
150,000 Added 3.53%
4,097,964 Common Stock
Nov 03 2020
BUY
Open market or private purchase
$5,062,000 $25.31 p/Share
200,000 Added 4.82%
3,947,964 Common Stock

Also insider at

MTEM
Molecular Templates, Inc. Healthcare
RDUS
Radius Health, Inc. Healthcare
MGNX
MACROGENICS INC Healthcare
TNV

Target N V Biotech

> 10% Shareholder
Curacao, P8

Track Institutional and Insider Activities on ESPR

Follow Esperion Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ESPR shares.

Notify only if

Insider Trading

Get notified when an Esperion Therapeutics, Inc. insider buys or sells ESPR shares.

Notify only if

News

Receive news related to Esperion Therapeutics, Inc.

Track Activities on ESPR